Patel, R., Harrington, K. J., Ahn, M., Licitra, L. F., Adkins, D., Daste, A., BraƱa, I., Yang, M., You, J., Xu, K., Monga, M., Guo, Y. (2025). A phase 2 study of first-line (1L) domvanalimab (dom), zimberelimab (zim), and chemotherapy (chemo) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Substudy-01 of the VELOCITY-HNSCC platform trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e18011